Edge Medical

Edge Medical emerged as a significant player in China’s surgical robotics sector following its successful Hong Kong Stock Exchange listing in January 2026. The Shenzhen-based company designs, develops, and manufactures surgical robots across three distinct platforms: multi-port laparoscopic systems, single-port laparoscopic systems, and natural orifice surgical robots.

Company Overview

Founded in May 2017 by Tianjin University alumni Wang Jianchen and Gao Yuanqing, Edge Medical achieved a notable distinction as the first company in China and second globally to receive NMPA regulatory approval for both multi-port and single-port laparoscopic surgical robots. The company completed its IPO on January 8, 2026, raising approximately HK$1.2 billion. Shares opened at HK$59, surging 36.45% above the IPO price of HK$43.24, with the market capitalization reaching HK$230 billion on the first trading day.

Prior to going public, Edge Medical completed multiple funding rounds totaling RMB 2.19 billion, with investors including Sequoia China, Temasek, Boyu Capital, Legend Star, and Tencent. The December 2021 cross-round financing valued the company at approximately RMB 10.6 billion.

Core Products

MP1000 Multi-Port Endoscopic Surgical Robot

The MP1000 received NMPA approval in December 2022 and CE Mark certification in March 2025. This four-arm robotic system provides seven degrees of freedom per arm and features a proprietary fluorescence imaging system—the only such approved functionality among Chinese-brand surgical robots. The upgraded MP1000 Plus, launched in August 2023, added dual console functionality for collaborative surgery and multimodal picture-in-picture integration.

As of June 2025, Edge Medical had signed cumulative global sales agreements for 61 MP1000 systems across more than 20 countries. In 2024, the company sold 20 MP1000 units domestically, ranking first among Chinese manufacturers in tender wins that year.

SP1000 Single-Port Endoscopic Surgical Robot

The SP1000 obtained NMPA approval in November 2023 and CE Mark certification in October 2025. According to Frost & Sullivan, it was the first domestically approved single-port laparoscopic surgical robot to cover three or more major surgical specialties. The system performs minimally invasive procedures through a single small incision, reducing surgical trauma and accelerating patient recovery.

By the last practicable date before IPO, over 2,000 robot-assisted clinical procedures had been completed using the SP1000 system.

Natural Orifice Bronchoscope Robot

Edge Medical received NMPA approval for its bronchoscope robot in January 2025 and commenced commercialization in September 2025. This system navigates through natural body openings using a flexible robotic endoscope, designed specifically for diagnostic and therapeutic bronchoscopy procedures in the lung periphery.

MSP2000 Multi-/Single-Port Super System

The MSP2000 achieved CE Mark certification alongside the SP1000 in October 2025, becoming the world’s first integrated single- and multi-port robotic surgical platform. This system-level integration combines the broad application scope of multi-port technology with the minimally invasive advantages of single-port approaches.

Technology & Innovation

Edge Medical’s technical capabilities extend beyond surgical hardware. The company’s “Edge Cloud” remote surgery system has completed over 500 procedures globally, including a 12,035-kilometer trans-oceanic operation that earned Guinness World Records certification. This telesurgery platform incorporates proprietary ROI encoding technology to achieve zero error in hand-eye coordination across intercontinental distances.

The company maintains full independent intellectual property rights across its product portfolio, with all commercialized products and pipeline candidates developed internally. Research and development investment totaled RMB 171 million in 2023, RMB 226 million in 2024, and RMB 97 million in the first half of 2025.

Market Presence

Edge Medical operates a production facility in Shenzhen with annual capacity exceeding 100 robot systems. The MP1000 has obtained regulatory clearance in 14 overseas jurisdictions across Europe, Asia-Pacific, the Middle East, Africa, and South America.

Domestically, over 12,000 robot-assisted clinical surgeries have been performed using the MP1000 system. The company is expanding its regional training center network, planning approximately 20 additional centers globally over the next two to three years.

Financial Performance

Revenue grew from RMB 48.0 million in 2023 to RMB 160 million in 2024, with first-half 2025 revenue reaching RMB 149 million. Gross margins have remained stable at approximately 61-63%. The company reported net losses of RMB 213 million in 2023, RMB 219 million in 2024, and RMB 89 million in the first half of 2025, reflecting ongoing investment in commercialization and R&D.

Key Milestones

• May 2017: Company established in Shenzhen
• December 2020: SP1000 approved by Beijing Institute of Medical Device Testing
• December 2022: MP1000 receives NMPA approval for urological surgeries
• August 2023: MP1000 Plus upgraded version launched
• November 2023: SP1000 receives NMPA approval
• January 2025: Bronchoscope robot receives NMPA approval
• March 2025: MP1000 receives CE Mark certification
• October 2025: SP1000 and MSP2000 receive CE Mark certification
• January 2026: Listed on Hong Kong Stock Exchange (2675.HK)

Frequently Asked Questions

What products does Edge Medical offer?

Edge Medical offers three main product lines: the MP1000 multi-port laparoscopic surgical robot, the SP1000 single-port laparoscopic surgical robot, and a natural orifice bronchoscope robot. The company also developed the MSP2000, an integrated platform combining both multi-port and single-port capabilities.

Is Edge Medical publicly traded?

Yes, Edge Medical listed on the Hong Kong Stock Exchange on January 8, 2026, under the stock code 2675.HK. The IPO raised approximately HK$1.2 billion with cornerstone investors including ADIA, Tencent, OrbiMed, and UBS Asset Management.

How does Edge Medical compare to Intuitive Surgical?

Edge Medical positions its MP1000 and SP1000 as domestic alternatives to Intuitive Surgical’s da Vinci platform. Clinical trials demonstrated that the MP1000 achieved efficacy and safety levels not inferior to the da Vinci system. Unlike da Vinci, Edge Medical offers an integrated single- and multi-port platform (MSP2000) and has developed remote surgery capabilities with intercontinental range.